NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky announces it has commenced an investigation of Dimension Therapeutics, Inc. (NASDAQ:DMTX) concerning possible violations of federal securities laws.
“subpar Factor IX scores on its gene therapy program for hemophilia B.”
On January 31, 2017, Dimension announced “preliminary topline safety and early efficacy results of Dimension’s study of DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B.” Though CEO Dr. Annalisa Jenkins noted that the Company was “encouraged” by the results, shares of Dimension fell from a prior close of $4.25 on January 30, 2017, to a close of $1.95 per share on January 31, 2017. John Carroll, analyst and Editor-in-Chief for Endpoints News, noted the study’s “subpar Factor IX scores on its gene therapy program for hemophilia B.” Caroll also noted that other companies are developing rival gene therapies which have “already boasted that four participants experienced consistent and sustained factor IX activity levels...” To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.